Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
NRAS mutation
Cancer:
Melanoma
Drug:
SBI-726
(
AKT inhibitor
,
mTORC1 inhibitor
,
NF-κB inhibitor
,
eIF4G1 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Cancer Res
Title:
SBI-0640756 attenuates the growth of clinically unresponsive melanomas by disrupting the eIF4F translation initiation complex
Excerpt:
SBI-756 and SBI-726 were more effective than BI-69A11 in attenuating colony formation by BRAF- and NRAS-mutant melanoma cells.
DOI:
10.1158/0008-5472.CAN-15-0885
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.